Skip to main content
. 2020 Oct 25;60(4):1784–1792. doi: 10.1093/rheumatology/keaa459

Fig. 3.

Fig. 3

Treatment response of the 19 included patients in the analysis

Treatment response was assessed by the 2016 ACR/EULAR TIS. Improvement was defined as a TIS of at least 40 by 9 weeks of IVIg treatment (dotted red line). Eight patients reached at least moderate improvement by 9 weeks of treatment (A), while 11 patients did not (B). TIS: Total Improvement Score.